MADRIGAL PHARMACEUTICALS, INC. — Form 8-K
Filed November 3, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Madrigal reported Q3 2026 Rezdiffra net sales of $431.3M (50% YoY growth), achieving blockbuster status with $1.1B year-to-date sales. The company reported net income of $55.4M ($1.83 diluted EPS)—its first profitable quarter—versus a net loss of $114.2M in Q3 2025. Patient count reached 55,850 (nearly doubled from Q3 2025), and cash position stood at $961.8M as of Sept. 30, 2026. The company initiated a new Phase 3 trial (MAESTRO-CSPH) targeting well-compensated cirrhosis (F4c) and appointed Dr. John C. Reed to the board.
Why this rating
First profitability milestone and blockbuster status ($1.1B YTD sales ≈ 20% of $5.6B market cap) represent genuine inflection point. Strong 50% revenue growth and robust cash position ($961.8M) support continued expansion, though growth deceleration risk and market maturation exist.
Price action (we called it positive)
before filing · preread $477.00 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.